Viet Nam Medicinal Materials JSC

Viet Nam Medicinal Materials JSC maintains a debt-to-equity ratio of 0.71, indicating a moderate reliance on debt financing relative to equity. The company's liquidity position is assessed as medium, with a current ratio of 0.99, suggesting limited short-term liquidity cushion. Despite a strong operating cash flow of VND 1.12 trillion, the company's cash and equivalents of VND 112.13 billion are insufficient to cover its long-term debt of VND 553.64 billion, resulting in a net cash deficit. Profitability metrics show a return on equity (ROE) of 5.15% and a return on assets (ROA) of 2.42%, both below the industry median for pharmaceuticals, which typically exceeds 10% ROE and 5% ROA. The company's net income of VND 39.96 billion is supported by a gross profit of VND 139.87 billion, but its operating margin of 3.45% is weak compared to the sector average of 15-20%. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of segmentation increases exposure to regional economic or regulatory shifts. No material international revenue is reported, suggesting a domestic focus. DVM.HN's revenue growth trajectory is not explicitly provided, but its operating cash flow has grown significantly, indicating potential operational expansion. The company's capital expenditures are minimal at VND 324.09 million, suggesting a conservative approach to reinvestment. However, the absence of disclosed revenue growth rates or future guidance limits visibility into its growth potential. Risk factors include a medium liquidity risk due to the current ratio of 0.99 and a net cash deficit. The company's dilution risk is assessed as low, with no recent share issuance or dilutive events reported. No material regulatory or geopolitical risks are disclosed, but the pharmaceutical industry is subject to policy changes and pricing pressures in Vietnam. Recent filings and transcripts are not provided in the input data, so no specific events can be cited. However, the company's financial snapshot suggests a stable but unremarkable performance, with no significant deviations from historical trends.